Carterra® continues successful antibody discovery seminars with new US East Coast event
Complete the form below to unlock access to ALL audio articles.
The Carterra LSA™ array SPR instrument has facilitated a paradigm shift in antibody discovery, enabling the rapid and detailed screening and characterization of large antibody libraries at the earliest stage of the discovery process. By performing both kinetic studies and epitope binning on all members of a library, rather than just a small subset, unique candidates can be identified to provide epitope diversity and IP coverage. The result is a streamlined and highly informed lead selection process. Crucially, researchers are now able to see greater detail within their antibody library, minimizing the risk of missing potentially high-value antibodies.
The recent West coast seminar held in San Francisco attracted over 50 attendees from a range of commercial companies and academic institutions, highlighting the increasing adoption of the Carterra LSA platform. With many opportunities for stimulating discussions and several new collaborations forged, presentations included:
• Jack Bevers III, Senior Scientific Researcher at Genentech, on the implementation of high throughput SPR into antibody discovery and engineering workflows
• Jacob Glanville, Chief Scientific Officer of Distributed Bio, who spoke about how computational immunoengineering and high throughput kinetic screening can realize the dream of a one-week antibody discovery cycle
• Kathryn Ching, Senior Scientist at Ligand Pharmaceuticals, discussed the use of high throughput SPR to validate next generation OmniChickens™
• Raphael Levy, PhD, Director, Antibody Engineering, LakePharma, who reviewed the discovery and characterization of Potent TIGIT-specific antibodies.
Further high profile industry leaders are scheduled for the December 5th seminar in Cambridge, MA, with presentations from Genentech, Adimab, Janssen Biotherapeutics, and Amgen.
“High throughput SPR is a disruptive technology that allows researchers to accelerate the library-to-leads process in antibody discovery because they can now perform detailed analysis on hundreds of interactions in parallel with minimal sample consumption”, said Yasmina Noubia Abdiche, PhD, Carterra’s Chief Scientific Officer. “Positioning SPR at the start of the drug discovery and development pipeline informs the selection of high-value candidates quickly and helps to determine their mechanism of action. Our seminar will allow attendees to learn about how Carterra’s LSA platform is transforming the discovery of therapeutic antibodies.”